124 related articles for article (PubMed ID: 3801271)
1. Combined effect of buthionine sulfoximine and cyclophosphamide upon murine tumours and bone marrow.
Ono K; Komuro C; Tsutsui K; Shibamoto Y; Nishidai T; Takahashi M; Abe M; Shrieve DC
Br J Cancer; 1986 Nov; 54(5):749-54. PubMed ID: 3801271
[TBL] [Abstract][Full Text] [Related]
2. Effect of glutathione depletion by L-buthionine sulfoximine on the cytotoxicity of cyclophosphamide in single and fractionated doses to EMT6/SF mouse tumors and bone marrow.
Ono K; Shrieve DC
J Natl Cancer Inst; 1987 Oct; 79(4):811-5. PubMed ID: 3477662
[TBL] [Abstract][Full Text] [Related]
3. In vivo therapeutic potential of combination thiol depletion and alkylating chemotherapy.
Siemann DW; Beyers KL
Br J Cancer; 1993 Dec; 68(6):1071-9. PubMed ID: 8260357
[TBL] [Abstract][Full Text] [Related]
4. Chemosensitization by buthionine sulfoximine in vivo.
Tsutsui K; Komuro C; Ono K; Nishidai T; Shibamoto Y; Takahashi M; Abe M
Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1183-6. PubMed ID: 2427490
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of EMT6/SF tumor cell killing by mitomycin C and cyclophosphamide following in vivo administration of buthionine sulfoximine.
Ono K; Shrieve DC
Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1175-8. PubMed ID: 3091546
[TBL] [Abstract][Full Text] [Related]
6. In vivo modulation of glutathione by buthionine sulfoximine: effect on marrow response to melphalan.
Russo A; Tochner Z; Phillips T; Carmichael J; DeGraff W; Friedman N; Fisher J; Mitchell JB
Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1187-9. PubMed ID: 3744938
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the protective effect of cyclophosphamide by pre-treatment with buthionine sulfoximine.
Carmichael J; Friedman N; Tochner Z; Adams DJ; Wolf CR; Mitchell JB; Russo A
Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1191-3. PubMed ID: 3744939
[TBL] [Abstract][Full Text] [Related]
8. Depletion of tumour versus normal tissue glutathione by buthionine sulfoximine.
Lee FY; Allalunis-Turner MJ; Siemann DW
Br J Cancer; 1987 Jul; 56(1):33-8. PubMed ID: 3620316
[TBL] [Abstract][Full Text] [Related]
9. Effect of systemic glutathione depletion by buthionine sulfoximine on sensitivity of murine bladder cancer to cytotoxic agents.
Lee KE; Mayer RD; Cockett AT
Urology; 1989 Dec; 34(6):376-80. PubMed ID: 2595883
[TBL] [Abstract][Full Text] [Related]
10. Lack of enhanced myelotoxicity with buthionine sulfoximine and sulfhydryl-dependent anticancer agents in mice.
Soble MJ; Dorr RT
Res Commun Chem Pathol Pharmacol; 1987 Feb; 55(2):161-80. PubMed ID: 3823607
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer.
O'Dwyer PJ; Hamilton TC; LaCreta FP; Gallo JM; Kilpatrick D; Halbherr T; Brennan J; Bookman MA; Hoffman J; Young RC; Comis RL; Ozols RF
J Clin Oncol; 1996 Jan; 14(1):249-56. PubMed ID: 8558205
[TBL] [Abstract][Full Text] [Related]
12. Lack of enhanced antitumor efficacy for L-buthionine sulfoximine in combination with carmustine, cyclophosphamide, doxorubicin or melphalan in mice.
Soble MJ; Dorr RT
Anticancer Res; 1988; 8(1):17-22. PubMed ID: 3358633
[TBL] [Abstract][Full Text] [Related]
13. Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione.
Bailey HH; Mulcahy RT; Tutsch KD; Arzoomanian RZ; Alberti D; Tombes MB; Wilding G; Pomplun M; Spriggs DR
J Clin Oncol; 1994 Jan; 12(1):194-205. PubMed ID: 8270977
[TBL] [Abstract][Full Text] [Related]
14. The effect of glutathione (GSH) depletion in vivo by buthionine sulfoximine (BSO) on the radiosensitization of SR 2508.
Kramer RA; Soble M; Howes AE; Montoya VP
Int J Radiat Oncol Biol Phys; 1989 May; 16(5):1325-9. PubMed ID: 2523885
[TBL] [Abstract][Full Text] [Related]
15. Radiosensitizing effect of misonidazole in combination with an inhibitor of glutathione synthesis in murine tumors.
Ono K; Komuro C; Nishidai T; Shibamoto Y; Tsutsui K; Takahashi M; Abe M
Int J Radiat Oncol Biol Phys; 1986 Sep; 12(9):1661-6. PubMed ID: 3759592
[TBL] [Abstract][Full Text] [Related]
16. Toxic effects of acute glutathione depletion by buthionine sulfoximine and dimethylfumarate on murine mammary carcinoma cells.
Dethlefsen LA; Lehman CM; Biaglow JE; Peck VM
Radiat Res; 1988 May; 114(2):215-24. PubMed ID: 3375425
[TBL] [Abstract][Full Text] [Related]
17. Relationship between thiol depletion and chemosensitization in a transplantable murine bladder tumor.
Tomashefsky P; Astor M; White RD
J Natl Cancer Inst; 1985 Jun; 74(6):1233-8. PubMed ID: 3858595
[TBL] [Abstract][Full Text] [Related]
18. Selective toxicity of buthionine sulfoximine (BSO) to melanoma cells in vitro and in vivo.
Révész L; Edgren MR; Wainson AA
Int J Radiat Oncol Biol Phys; 1994 May; 29(2):403-6. PubMed ID: 8195041
[TBL] [Abstract][Full Text] [Related]
19. Glutathione depletion by L-buthionine sulfoximine antagonizes taxol cytotoxicity.
Liebmann JE; Hahn SM; Cook JA; Lipschultz C; Mitchell JB; Kaufman DC
Cancer Res; 1993 May; 53(9):2066-70. PubMed ID: 8097674
[TBL] [Abstract][Full Text] [Related]
20. Augmentation of cisplatin (DDP) cytotoxicity in vivo by DL-buthionine sulfoximine (BSO) in DDP-sensitive and-resistant rat ovarian tumors and its relation to DNA interstrand cross links.
Chen G; Zeller WJ
Anticancer Res; 1991; 11(6):2231-7. PubMed ID: 1776864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
